Back to search results
NCT06359665

Oral Curcumin for the Treatment of Pain of Thumb Base Joint (CMC) Arthritis

Enrolling by Invitation
PHASE1Ages 18+InterventionalTreatment
Brent DeGeorge
~100 participants
Updated 2025-12-19 on ClinicalTrials.gov
What's tested:CurcuminPlacebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from Baseline in Pain on the Visual Analog Pain (VAS) Score
Measured over Baseline and Week 4, Week 6
+1 more outcome measured

Conditions

Arthritis of Carpometacarpal Joint of Left Thumb
Arthritis of Carpometacarpal Joint of Right Thumb

Explore related trials

Thumb Carpometacarpal Osteoarthritis

Where it's being run

1 sites across 1 states
Virginia1

Study leadership

  • Brent DeGeorge, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Virginia Department of Plastic Surgery

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Norplant
IUD (intrauterine device)
Birth Control Patch
Depo-Provera
Sterilization
Condoms
Diaphragm
Jellies or foam
Cervical cap
Sponge 5. For males, must be willing to not father a baby for the duration of the study and for 90 days after the last dose of study drug, or donate to a sperm back during this time. Must be willing to use an approved form of birth control during this time. Acceptable forms of birth control:
Condoms
Sterilization 6. Daily visual analog pain greater than 5 and ≤ 9 out of 10. 7. Duration of pain for greater than 30 days. 8. Presence of radiographically confirmed diagnosis of thumb basal joint arthritis

Exclusion

Itraconazole,
Ketoconazole,
Azamulin,
Troleandomycin,
Verapamil,
John's wart,
Phenobarbital, 16. Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates of CYP2C19:
Nootkatone,
Ticlopidine,
Rifampin,
Omeprazole), 17. Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates of CYP2C8:
Montelukast,
Quercetin,
Phenelzine,
Rifampin,
Clopidogrel , 18. Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates of CYP2C9:
Sulfaphenazole,
Tienilic acid,
Carbamazepine,
Apoflutamide ,
Fluconazole,
Celecoxib, 19. Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates of CYP1A2:
alpha-Naphthoflavone,
Furafylline,
Phenytoin,
Rifampin,
Ritonavir,
smoking,
Teriflunomide,
Ciprofloxacin,
oral contraceptives,
Allopurinol 20. Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates of CYP2B6 :
Sertraline,
Phencyclidine,
Thiotepa,
Ticlopidine,
Carbamazepine,
Efavirenz,
Rifampin,
Bupropion)

What this trial measures

  • Change from Baseline in Pain on the Visual Analog Pain (VAS) ScoreBaseline and Week 4, Week 6

    The Visual Analog Pain (VAS) Score is a validated, self-reported subjective measure for measuring acute and chronic pain. Possible scores range from 0 (no pain) to 10 (worst possible pain). Change = (Week (4 or 6) Score - Baseline Score).a validated, self-report

  • Change from Baseline in Pain on the Visual Analog Pain (VAS) Score - crossover conditionBaseline and Week 10, Week 12

    The Visual Analog Pain (VAS) Score is a validated, self-reported subjective measure for measuring acute and chronic pain. Possible scores range from 0 (no pain) to 10 (worst possible pain). Change = (Week Change = (Week (10 or 12) Score - Baseline Score).